A Rare Approach Widens the Moat for This Biotech
Alexion's diversifying pipeline and focus on attractive rare-disease markets are strengthening its competitive position.
Alexion's diversifying pipeline and focus on attractive rare-disease markets are strengthening its competitive position.
Stefan Quenneville: We think that Alexion (ALXN) is a biotech company that has a widening moat because of its broadening pipeline, which was helped by its recent acquisition of Synageva BioPharma, and its strategy to focus on attractive rare-disease markets.
Unlike most pharma and biotech companies that are typically interested in diseases that affect a lot of people like diabetes or asthma, Alexion focuses on rare and severe afflictions that only impact a few thousand people globally. So, while rare diseases makes it sound like a small opportunity, this is actually an area with some of the strongest pricing power in the drug industry, particularly for very effective drugs that treat serious chronic disorders. Rare-disease markets also tend to have less competition and a more welcoming regulatory pathway.
In Alexion's case, its only marketed drug, Soliris, costs about $500,000 a year because it is such an effective treatment for two very rare and deadly blood disorders. The drug currently has revenues of about $2.5 billion and has a peak sales potential of about $5 billion. In its pipeline, the company has two more ultra-rare-disease drugs that should be approved in the second half of this year and both have blockbuster potential. One of these drugs comes from [Alexion's] recent acquisition of Synegeva, which also added several early-stage assets to its pipeline.
Given its diversifying pipeline and the attractive competitive dynamics of rare-disease markets, we think Alexion's competitive position is strengthening. From a valuation perspective, the stock is currently trading at a discount to our fair value estimate of $175 per share. So, we think this could be an interesting time for investors to take a look at the stock.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.